Cencora, Inc. $COR is Carmignac Gestion’s 5th Largest Position

Carmignac Gestion lifted its position in shares of Cencora, Inc. (NYSE:COR) by 25.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,101,251 shares of the company’s stock after buying an additional 226,156 shares during the quarter. Cencora makes up about 5.3% of Carmignac Gestion’s holdings, making the stock its 5th largest position. Carmignac Gestion owned about 0.57% of Cencora worth $345,930,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. ExodusPoint Capital Management LP purchased a new position in Cencora during the fourth quarter worth $16,487,000. Assetmark Inc. raised its holdings in shares of Cencora by 57.0% in the fourth quarter. Assetmark Inc. now owns 67,281 shares of the company’s stock worth $22,724,000 after acquiring an additional 24,431 shares during the last quarter. Impact Partnership Wealth LLC purchased a new stake in shares of Cencora in the first quarter valued at $1,170,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Cencora by 162.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 289,370 shares of the company’s stock valued at $97,735,000 after acquiring an additional 179,086 shares during the last quarter. Finally, SEB Asset Management AB acquired a new stake in shares of Cencora during the first quarter valued at $134,139,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Cencora

In related news, Director Lauren M. Tyler purchased 550 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $270.23 per share, with a total value of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.38% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the subject of a number of recent research reports. Weiss Ratings cut Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 30th. Citigroup reduced their target price on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Barclays decreased their price target on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 10th. William Blair started coverage on shares of Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating for the company. Finally, Wells Fargo & Company reduced their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. Eleven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $367.75.

Cencora Stock Performance

NYSE COR opened at $312.40 on Monday. The business’s 50-day moving average price is $289.36 and its 200 day moving average price is $315.41. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The company has a market capitalization of $60.78 billion, a PE ratio of 23.96, a price-to-earnings-growth ratio of 1.73 and a beta of 0.57. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same period in the previous year, the business posted $4.42 earnings per share. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, research analysts predict that Cencora, Inc. will post 17.8 earnings per share for the current year.

Cencora announced that its Board of Directors has initiated a stock buyback plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to purchase up to 3.9% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s payout ratio is presently 18.40%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.